Chris joins NeoGenomics from OrthoClinical Diagnostics where he served as Chairman and CEO from 2019 to May of 2022. During his leadership, OrthoClinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.
Prior to OrthoClinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.
Jeff has over 32 years of finance experience in the healthcare services industry, having gained a well-rounded background from serving in finance roles at public companies of different sizes and at different growth stages in their lifecycle. While he has most recently served as Chief Financial Officer of Privia Health Group, Inc., a national physician enablement company, Jeff has also served as the Chief Financial Officer at three other organizations: HMS, a technology analytics and engagement solutions provider for government and commercial healthcare payers; AccentCare, a multi-state community-based healthcare delivery organization; and LIFEPOINT Health, a non-urban private hospital company operating 72 hospitals. Jeff also held various finance roles of increasing scope and responsibility at Tenet Healthcare Corporation.
Jeff received a B.A. in Finance/Accounting from the University of Colorado, Boulder, and an MBA from the University of Southern California.
When not working, he enjoys running, biking outside, hiking, and skiing with his family.
Melody Harris joined NeoGenomics in December of 2022. She is serving as President of Enterprise Operations. Prior to that Melody was with SomaLogic and served as President and Chief Operating Officer. She oversaw life sciences markets, healthcare markets, marketing and product, operations, technology, legal and HR. Ms. Harris assisted the CEO in day-to-day management of the company both internally and external, with full P&L responsibility.
Prior to SomaLogic, Ms. Harris held executive positions in the healthcare space for Qualcomm Life (the healthcare division of Qualcomm) and HealthyCircles, a technology spin-out from Microsoft which she and team successfully sold to Qualcomm in 2013. At Qualcomm, Ms. Harris led corporate deals and M&A transactions and worked extensively across Qualcomm in leading the integration efforts of those acquisitions. Ms. Harris has led deals across the healthcare spectrum including with Merck, Telus Health Solutions, United Health Group, Novartis, Surescripts, CVS and the American Heart Association to name a few.
Prior to HealthyCircles, Ms. Harris held a variety of other executive, operational and legal leadership roles, including president of an international consumer-focused brand management firm, and executive vice president of an international software development and consulting firm in the broadcasting space.
Ms. Harris has served in multiple community and public roles including as a trustee of Metropolitan State University of Denver (gubernatorial appointment), director of the Stapleton Development Corporation (mayoral appointment), member of two Colorado gubernatorial transition committees, policy advisor to Denver Mayor Michael Hancock and member of his transition team, and energy policy advisor and lead writer of the Bill Ritter for Governor campaign’s New Energy Economy white paper in 2006.
Ms. Harris holds a Bachelor of Arts, cum laude, in Political Science from the University of Denver and a Juris Doctor, cum laude, from the Harvard Law School. Her full profile is available at www.linkedin.com/in/melody-harris-175b7ba.
Warren is a highly accomplished enterprise leader with extensive global experience in the Life Science and Diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics.
As a hands-on leader, Warren championed the development of an organizational growth culture and digital transformation of systems and tools, including a hybrid/digital go-to-market deployment model, delivering productivity, margin expansion and accelerated revenue growth. With an emphasis on customer experience, Warren's team won an independent industry ServiceTrak™ award for the 'Best Pre/Post-Sales and Customer Success in 2021 and 2022'.
Before joining Ortho, he served as Senior Vice President of Research Americas for MilliporeSigma, where he developed a commercial growth strategy, advancing the business 40% above the market. He also drove a cross-functional digital transformation to address customer needs, resulting in more than $200M in incremental revenue in 2.5 years.
President of Lab Operations and Chief Scientific Officer
Shashikant Kulkarni President of Lab Operations and Chief Scientific Officer
Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. At Baylor, he led an extensive clinical and translational research team, delivering top-quality clinical genomics and multi-omics tools.
Dr. Kulkarni is considered a world-renowned expert and key opinion leader in cancer genomics with a focus on applying genomic and multi-omic technologies to improve the understanding of human disease and the precision of clinical diagnosis, prognosis, and treatment. He has given numerous national and international presentations and, as a leading voice, presented his insight, thoughts, and opinions as a frequent guest on multiple major news outlets across the country. Additionally, he has published extensively in peer-reviewed articles and numerous well-known journals. He is the Editor-in-Chief of Cancer Genetics Journal and has co-edited a book, available on Amazon, titled Clinical Genomics – A Guide to Clinical Next-Generation Sequencing.
President Pharma Services, President and Chief Commercial Officer Inivata
Vishal Sikri President Pharma Services, President and Chief Commercial Officer Inivata
Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis leading all commercial operations. He has extensive precision medicine experience, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms. Vishal brings years of proven success as a dynamic leader in large organizations. He holds degrees in Molecular Biology and Pharmaceutical Sciences from UW-Madison and an MBA from Loyola University.
Kathryn B. McKenzie Chief Sustainability and Risk Officer
Kathryn McKenzie serves as Chief Sustainability and Risk Officer for NeoGenomics. In this role, she oversees our environmental, social and governance initiatives as well as our risk management activities.
She joined NeoGenomics in 2017 as our Chief Accounting Officer and Vice President of Finance and was most recently our Chief Financial Officer through December 2021. Prior to joining NeoGenomics, Ms. McKenzie served in various roles at Chico’s FAS, including as Assistant Controller and had responsibilities for SEC reporting, accounting, cash management and treasury. Ms. McKenzie began her career at Ernst and Young in assurance, primarily serving financial institutions and healthcare clients. Ms. McKenzie is a Certified Public Accountant and holds a Master's of Science in Accountancy from the University of North Carolina Wilmington.
Gary Passman, Chief Culture Officer at NeoGenomics, is responsible for Neo’s strategy regarding its most important asset – its people. Cultivating an engaging culture focused on how the company works in support of all teammates and customers is critical to Neo’s success.
Gary has over 20 years of experience across several disciplines within the People & Culture, or Human Resources, function - with both regional and global responsibilities. He joined Neo in early 2023. Prior to joining Neo, he held numerous business partner and specialty area positions within HR across Johnson & Johnson. Most recently Gary was the Head of Global People & Culture for Ortho Clinical Diagnostics from 2019 to 2022/
He holds a Bachelor of Arts degree in economics, as well as a master’s degree in human resource management, from Rutgers University.
John Mooney was named NeoGenomics’ Chief Technology Officer in 2021.
Prior to joining the company, John held several roles of increasing responsibility at BioReference Laboratories and served as their Chief Information Officer from 2016 – 2021. During his tenure at BioReference, the company revenues grew from $422M to greater than $1.4B.
Earlier in his career, John worked for several software companies and was the founding architect for two successful digital health startups. He is a subject matter expert in healthcare interoperability, having shaped standards for HL7 and ONC.
John holds a B.S. in Operations & Information Management from the University of Scranton.
Marcus B. Silva, JD, MBA
Senior Vice President & General Manager - Oncology Diagnostics
Marcus B. Silva, JD, MBA Senior Vice President & General Manager - Oncology Diagnostics
Mr. Silva has over 17 years of sales, marketing and general management experience in healthcare delivery, medical devices and diagnostics, and pharmaceuticals. Mr. Silva joined NeoGenomics in June 2020 as the Chief Marketing Officer, after leading Precision Medicine efforts at Novartis resulting in the the successful 2019 launch of PIQRAY (alpelisib) and 2020 launch of TABRECTA (capmatinib).
Prior to Novartis, Mr. Silva was with Becton Dickinson (BD) where he first led global strategic marketing excellence for their $1B global injection business and later was appointed head of Marketing and Analytics for their $700M US Diabetes Care business. Prior to BD, Mr. Silva was with Johnson & Johnson’s Ortho-Clinical Diagnostics franchise, where he held various leadership roles within Global Marketing, Strategic Marketing and Regional Marketing, including multiple product and campaign launches. Prior to this, Mr. Silva started his own healthcare company based in Southern California that focused on senior care, which he ran for almost 10 years and grew to over 100 employees. Additionally, Mr. Silva began his career as a practicing California plaintiff’s attorney, litigating employment law cases in Southern California.
Mr. Silva earned his BA from Rutgers University, his JD from California Western School of Law, and his MBA from Rutgers Business School, with a focus on Marketing and Pharmaceutical Management.
Hutan most recently served as Chief Compliance Officer at Progenity, Inc., a women's health diagnostics company. A strategic and tactical executive, he counseled all levels of the organization, including the Board of Directors and executive management, on legal, compliance, and privacy issues facing the life sciences and biotech industry. Before joining Progenity in 2019, Mr. Hashemi was the Chief Compliance Officer at Genoptix, Inc., before the merger with NeoGenomics in 2018. Earlier in Hutan's legal career, he worked in private practice at law firms advising real estate and financial clients on a wide range of commercial, regulatory, corporate, litigation, and intellectual property matters.
Hutan's experience and background accentuate our unwavering commitment to achieving high compliance standards across our organization.
Ali Olivio General Counsel and Corporate Secretary
Ali has been serving as Interim General Counsel since mid-April 2022.
Ms. Olivo has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for nearly three years representing NeoGenomics in its acquisition of Inivata and Trapelo, as well as fundraising and governance activities. At Neo, she has also represented the company in various regulatory matters, including before CAP, OCR, and the OIG.
Prior to joining NeoGenomics, Ms. Olivo served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. Ms. Olivo also spent many years at General Electric in various roles, increasing scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs